FDA Granted Breakthrough Status to Sepsis Device

The FDA awarded Breakthrough Device Designation to SeaStar Medical's SCD therapy for treating sepsis hyperinflammation.

Updated on Oct. 7, 2026 in Diabetes

Isometric editorial illustration of a modular medical filtration cartridge, rendered in clean, flat-colored geometric forms. — The FDA granted Breakthrough Device Designation to SeaStar Medical's SCD therapy, a system designed to treat hyperinflammation in adults with sepsis. AI Illustration. Upload story photo >

Live Poll

Should regulatory agencies accelerate approval pathways for experimental medical devices to treat life-threatening conditions?

The FDA has granted Breakthrough Device Designation to the SeaStar Medical SCD therapy, a system designed to treat hyperinflammation in adults with sepsis. This designation aims to expedite the development and review process for medical devices that offer more effective treatments for life-threatening conditions.

Why it matters

Sepsis impacts approximately 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths, yet there are currently no FDA-approved therapies to address dysregulated inflammatory host responses. This designation provides a critical pathway to accelerate the assessment of a device that could change patient outcomes.

Sepsis affects 1.7 million U.S. adults every year and accounts for nearly one-third of all hospital deaths. This status marks the seventh Breakthrough Device Designation for the SCD therapy, which integrates with existing continuous hemofiltration systems.

The players

SeaStar Medical

This Denver-based medical technology company focuses on developing proprietary therapies to address hyperinflammation in critically ill patients.

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and drugs.

The details

The SCD therapy targets proinflammatory monocytes to transition them into a reparative state, potentially stabilizing the patient during septic episodes. SeaStar Medical plans to submit additional data to the FDA in the near term as it seeks approval for this specific indication.

In 2024, the FDA approved QUELIMMUNE.
QUELIMMUNE SAVE Registry data was published in February 2026.
The FDA granted the Breakthrough Device Designation on October 7, 2026.

The Big Picture

This designation follows the FDA Breakthrough Device Designation program, which is designed to provide patients with more timely access to medical devices that treat life-threatening conditions. The development of the SCD therapy positions the company at the forefront of efforts to address dysregulated immune responses where traditional medicine has lacked targeted options.

This designation does not immediately change treatment options, but it signals progress toward potentially life-saving interventions for sepsis patients in the future. Once approved, such therapies could shift clinical standards for managing severe inflammation in hospital settings.

The takeaway

The FDA's decision recognizes the urgent clinical need for novel sepsis treatments by streamlining the development pathway for this technology. Patients and healthcare providers should monitor future clinical trial results as the device undergoes further assessment.